<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39424598</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2055-6845</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>European heart journal. Cardiovascular pharmacotherapy</Title><ISOAbbreviation>Eur Heart J Cardiovasc Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.</ArticleTitle><Pagination><StartPage>728</StartPage><EndPage>737</EndPage><MedlinePgn>728-737</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcvp/pvae071</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms in this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycaemic control, reduce body weight, and reduce the risk of major adverse cardiovascular events in people with atherosclerotic cardiovascular disease and type 2 diabetes (T2D).</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">STRIDE (NCT04560998) is a randomized, placebo-controlled, double-blind phase 3b trial evaluating 1&#xa0;mg once-weekly subcutaneous semaglutide (GLP-1 RA) vs. placebo, in people with symptomatic PAD (Fontaine IIa claudication) and T2D. Eligible participants were &#x2265;18 years, had haemodynamically stable PAD, had no planned intervention, and were not receiving a GLP-1 RA. The primary endpoint is change in maximum walking distance on a constant-load treadmill (CLT). Secondary endpoints include quality of life and cardiometabolic assessments. A total of 792 participants were randomized in 20 countries. Participants' median age was 68 and median T2D duration 12 years. Risk factors included 25.6% current smokers, 87.9% with hypertension, and 42.7% with coronary heart disease. The mean BMI was 29.6&#xa0;kg/m2 and the mean HbA1C was 7.3%. Participants exhibited baseline functional impairment with a median maximum walking distance of 186 m on a CLT.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">STRIDE has enrolled participants with symptomatic PAD and T2D, frequent risk factors and comorbidities, and functional impairment. The trial will provide evidence for the functional outcomes with semaglutide in people with PAD and T2D.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonaca</LastName><ForeName>Marc P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-9860-3584</Identifier><AffiliationInfo><Affiliation>CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catarig</LastName><ForeName>Andrei-Mircea</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Yasemin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houlind</LastName><ForeName>Kim</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1600-4415</Identifier><AffiliationInfo><Affiliation>Department of Vascular Surgery, Lillebaelt Hospital.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regional Health Research, University of Southern Denmark, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramesh</LastName><ForeName>Chethana Kalmady</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Novo Nordisk GBS India, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludvik</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders Landstrasse Clinic, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordanstig</LastName><ForeName>Joakim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2670-2268</Identifier><AffiliationInfo><Affiliation>Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasouli</LastName><ForeName>Neda</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1269-3580</Identifier><AffiliationInfo><Affiliation>School of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sourij</LastName><ForeName>Harald</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3510-9594</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Subodh</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4018-8533</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, St. Michael's Hospital, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Novo Nordisk</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Cardiovasc Pharmacother</MedlineTA><NlmUniqueID>101669491</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>62340-29-8</RegistryNumber><NameOfSubstance UI="D004763">Glucagon-Like Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054795">Incretins</NameOfSubstance></Chemical><Chemical><RegistryNumber>53AXN4NNHX</RegistryNumber><NameOfSubstance UI="C000591245">semaglutide</NameOfSubstance></Chemical><Chemical><RegistryNumber>89750-14-1</RegistryNumber><NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017079" MajorTopicYN="N">Exercise Tolerance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004763" MajorTopicYN="Y">Glucagon-Like Peptides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054795" MajorTopicYN="Y">Incretins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007383" MajorTopicYN="Y">Intermittent Claudication</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058729" MajorTopicYN="Y">Peripheral Arterial Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070857" MajorTopicYN="N">Walk Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052216" MajorTopicYN="N" AutoHM="Y">Glucagon-Like Peptide 1</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GLP1 agonist</Keyword><Keyword MajorTopicYN="N">Maximal walking distance</Keyword><Keyword MajorTopicYN="N">PAD</Keyword><Keyword MajorTopicYN="N">Peripheral artery disease</Keyword><Keyword MajorTopicYN="N">Semaglutide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>12</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>22</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39424598</ArticleId><ArticleId IdType="pmc">PMC11724141</ArticleId><ArticleId IdType="doi">10.1093/ehjcvp/pvae071</ArticleId><ArticleId IdType="pii">7826783</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Song &#xa0;P, Rudan &#xa0;D, Zhu &#xa0;Y, Fowkes &#xa0;FJI, Rahimi &#xa0;K, Fowkes &#xa0;FGR, Rudan &#xa0;I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health &#xa0;2019;7:e1020&#x2013;e1e30.</Citation><ArticleIdList><ArticleId IdType="pubmed">31303293</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah &#xa0;AD, Langenberg &#xa0;C, Rapsomaniki &#xa0;E, Denaxas &#xa0;S, Pujades-Rodriguez &#xa0;M, Gale &#xa0;CP, Deanfield &#xa0;J, Smeeth &#xa0;L, Timmis &#xa0;A, Hemingway &#xa0;H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol &#xa0;2015;3:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303913</ArticleId><ArticleId IdType="pubmed">25466521</ArticleId></ArticleIdList></Reference><Reference><Citation>Criqui &#xa0;MH, Matsushita &#xa0;K, Aboyans &#xa0;V, Hess &#xa0;CN, Hicks &#xa0;CW, Kwan &#xa0;TW, McDermott &#xa0;MM, Misra &#xa0;S, Ujueta &#xa0;F, &#xa0;American Heart Association Council on Epidemiology and Prevention, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention,&#xa0;Council on Lifestyle and Cardiometabolic Health,&#xa0;Council on Peripheral Vascular Disease; and Stroke Council . Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation &#xa0;2021;144:e171&#x2013;e91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847212</ArticleId><ArticleId IdType="pubmed">34315230</ArticleId></ArticleIdList></Reference><Reference><Citation>Behan &#xa0;SA, Mulder &#xa0;H, Rockhold &#xa0;FW, Gutierrez &#xa0;JA, Baumgartner &#xa0;I, Katona &#xa0;BG, Mahaffey &#xa0;KW, Norgren &#xa0;L, Jones &#xa0;WS, Bonaca &#xa0;MP. Impact of polyvascular disease and diabetes on limb and cardiovascular risk in peripheral artery disease. J Am Coll Cardiol &#xa0;2022;79:1781&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">35483761</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman &#xa0;JA, Duncan &#xa0;MS, Damrauer &#xa0;SM, Wells &#xa0;QS, Barnett &#xa0;JV, Wasserman &#xa0;DH, Bedimo &#xa0;RJ, Butt &#xa0;AA, Marconi &#xa0;VC, Sico &#xa0;JJ, Tindle &#xa0;HA, Bonaca &#xa0;MP, Aday &#xa0;AW, Freiberg &#xa0;MS. Microvascular disease, peripheral artery disease, and amputation. Circulation &#xa0;2019;140:449&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6682431</ArticleId><ArticleId IdType="pubmed">31280589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcdermott &#xa0;MM, Ho &#xa0;KJ, Alabi &#xa0;O, Criqui &#xa0;MH, Goodney &#xa0;P, Hamburg &#xa0;N, Mcneal &#xa0;DM, Pollak &#xa0;A, Smolderen &#xa0;KG, Bonaca &#xa0;M. Disparities in diagnosis, treatment, and outcomes of peripheral artery disease: JACC scientific statement. J Am Coll Cardiol &#xa0;2023;82:2312&#x2013;2328.</Citation><ArticleIdList><ArticleId IdType="pubmed">38057074</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma &#xa0;S, Al&#x2010;Omran &#xa0;M, Leiter &#xa0;LA, Mazer &#xa0;CD, Rasmussen &#xa0;S, Saevereid &#xa0;HA, Sejersten Ripa &#xa0;M, Bonaca &#xa0;MP. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab &#xa0;2022;24:1288&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325529</ArticleId><ArticleId IdType="pubmed">35332654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoff &#xa0;AM, Brown-Frandsen &#xa0;K, Colhoun &#xa0;HM, Deanfield &#xa0;J, Emerson &#xa0;SS, Esbjerg &#xa0;S, Hardt-Lindberg &#xa0;S, Hovingh &#xa0;GK, Kahn &#xa0;SE, Kushner &#xa0;RF, Lingvay &#xa0;I, Oral &#xa0;TK, Michelsen &#xa0;MM, Plutzky &#xa0;J, Torn&#xf8;e &#xa0;CW, Ryan &#xa0;DH. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med &#xa0;2023;389:2221&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pubmed">37952131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingvay &#xa0;I, Brown&#x2010;Frandsen &#xa0;K, Colhoun &#xa0;HM, Deanfield &#xa0;J, Emerson &#xa0;SS, Esbjerg &#xa0;S, Hardt&#x2010;Lindberg &#xa0;S, Hovingh &#xa0;GK, Kahn &#xa0;SE, Kushner &#xa0;RF, Lincoff &#xa0;AM, Marso &#xa0;SP, Fries &#xa0;TM, Plutzky &#xa0;J, Ryan &#xa0;DH. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring) &#xa0;2023;31:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10107832</ArticleId><ArticleId IdType="pubmed">36502289</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhatariya &#xa0;K, Bain &#xa0;SC, Buse &#xa0;JB, Simpson &#xa0;R, Tarnow &#xa0;L, Kaltoft &#xa0;MS, Stellfeld &#xa0;M, Torn&#xf8;e &#xa0;K, Pratley &#xa0;RE. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with Type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial. Diabetes Care &#xa0;2018;41:2229&#x2013;2235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6150424</ArticleId><ArticleId IdType="pubmed">30072400</ArticleId></ArticleIdList></Reference><Reference><Citation>Park &#xa0;B, Bakbak &#xa0;E, Teoh &#xa0;H, Krishnaraj &#xa0;A, Dennis &#xa0;F, Quan &#xa0;A, Rotstein &#xa0;OD, Butler &#xa0;J, Hess &#xa0;DA, Verma &#xa0;S. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol &#xa0;2024;326:H1159&#x2013;H1H76.</Citation><ArticleIdList><ArticleId IdType="pubmed">38426865</ArticleId></ArticleIdList></Reference><Reference><Citation>Aday &#xa0;AW, Matsushita &#xa0;K. Epidemiology of peripheral artery disease and polyvascular disease. Circ Res &#xa0;2021;128:1818&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8202714</ArticleId><ArticleId IdType="pubmed">34110907</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber &#xa0;A, Menard &#xa0;MT, Bonaca &#xa0;MP, Bradbury &#xa0;A, Conte &#xa0;MS, Debus &#xa0;ES, Eldrup &#xa0;N, Goodney &#xa0;P, Gupta &#xa0;PC, Hinchliffe &#xa0;RJ, Houlind &#xa0;KC, Kolh &#xa0;P, Kum &#xa0;SWC, Nordanstig &#xa0;J, Parikh &#xa0;SA, Patel &#xa0;MR, Patrone &#xa0;L, Sillesen &#xa0;H, Strong &#xa0;MB, Varcoe &#xa0;RL, Vega de Ceniga &#xa0;M, Venermo &#xa0;MA, Rosenfield &#xa0;K. BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally. Br J Surg &#xa0;2024;111:znad413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10828928</ArticleId><ArticleId IdType="pubmed">38294083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcdermott &#xa0;MM, Tian &#xa0;L, Zhang &#xa0;D, Zhao &#xa0;L, Greenland &#xa0;P, Kibbe &#xa0;MR, Criqui &#xa0;MH, Thangada &#xa0;ND, Ferrucci &#xa0;L, Ho &#xa0;KJ, Guralnik &#xa0;JM, Polonsky &#xa0;TS. Discordance of patient-reported outcome measures with objectively assessed walking decline in peripheral artery disease. J Vasc Surg &#xa0;2024;79:893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">38122859</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee &#xa0;M, Gornik &#xa0;HL, Aronow &#xa0;HD, Goodney &#xa0;PP, Arya &#xa0;S, Brewster &#xa0;LP, Byrd &#xa0;L, Chandra &#xa0;V, Drachman &#xa0;DE, Eaves &#xa0;JM, Ehrman &#xa0;JK. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol &#xa0;2024;83:2497&#x2013;2604.</Citation><ArticleIdList><ArticleId IdType="pubmed">38752899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcdermott &#xa0;MM, Guralnik &#xa0;JM, Tian &#xa0;L, Liu &#xa0;K, Ferrucci &#xa0;L, Liao &#xa0;Y, Sharma &#xa0;L, Criqui &#xa0;MH. Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study). J Am Coll Cardiol &#xa0;2009;53:1056&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215766</ArticleId><ArticleId IdType="pubmed">19298919</ArticleId></ArticleIdList></Reference><Reference><Citation>Divakaran &#xa0;S, Carroll &#xa0;BJ, Chen &#xa0;S, Shen &#xa0;C, Bonaca &#xa0;MP, Secemsky &#xa0;EA. Supervised exercise therapy for symptomatic peripheral artery disease among medicare beneficiaries between 2017 and 2018: participation rates and outcomes. Circ Cardiovasc Qual Outcomes &#xa0;2021;14:e007953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373731</ArticleId><ArticleId IdType="pubmed">34293930</ArticleId></ArticleIdList></Reference><Reference><Citation>Beebe &#xa0;HG, Dawson &#xa0;DL, Cutler &#xa0;BS, Herd &#xa0;JA, Strandness &#xa0;DE, Bortey &#xa0;EB, Forbes &#xa0;WP. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med &#xa0;1999;159:2041&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">10510990</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson &#xa0;DL, Cutler &#xa0;BS, Meissner &#xa0;MH, Strandness &#xa0;DE &#xa0;Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation &#xa0;1998;98:678&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">9715861</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson &#xa0;DL, Cutler &#xa0;BS, Hiatt &#xa0;WR, Hobson &#xa0;RW, Martin &#xa0;JD, Bortey &#xa0;EB, Forbes &#xa0;WP, Strandness &#xa0;DE. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med &#xa0;2000;109:523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063952</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca &#xa0;MP, Hess &#xa0;C, Beckman &#xa0;JA. Telmisartan and walking performance in peripheral artery disease. JAMA &#xa0;2022;328:1302&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">36194236</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee, &#xa0;Birtcher &#xa0;KK, Allen &#xa0;LA, Anderson &#xa0;JL, Bonaca &#xa0;MP, Gluckman &#xa0;TJ, Hussain &#xa0;A, Kosiborod &#xa0;M, Mehta &#xa0;LS, Virani &#xa0;SS. 2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol &#xa0;2023;81:292&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">36307329</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca &#xa0;MP, Wiviott &#xa0;SD, Zelniker &#xa0;TA, Mosenzon &#xa0;O, Bhatt &#xa0;DL, Leiter &#xa0;LA, Mcguire &#xa0;DK, Goodrich &#xa0;EL, De Mendonca Furtado &#xa0;RH, Wilding &#xa0;JPH, Cahn &#xa0;A, Gause-Nilsson &#xa0;IAM, Johanson &#xa0;P, Fredriksson &#xa0;M, Johansson &#xa0;PA, Langkilde &#xa0;AM, Raz &#xa0;I, Sabatine &#xa0;MS. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation &#xa0;2020;142:734&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">32795086</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma &#xa0;S, Dhingra &#xa0;NK, Bonaca &#xa0;MP, Butler &#xa0;J, Anker &#xa0;SD, Ferreira &#xa0;JP, Filippatos &#xa0;G, Januzzi &#xa0;JL, Lam &#xa0;CSP, Sattar &#xa0;N, Iwata &#xa0;T, Nordaby &#xa0;M, Brueckmann &#xa0;M, Pocock &#xa0;SJ, Packer &#xa0;M. Presence of peripheral artery disease is associated with increased risk of heart failure events: insights from EMPEROR-Pooled. Arterioscler Thromb Vasc Biol &#xa0;2023;43:1334&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10281175</ArticleId><ArticleId IdType="pubmed">37199158</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso &#xa0;SP, Bain &#xa0;SC, Consoli &#xa0;A, Eliaschewitz &#xa0;FG, J&#xf3;dar &#xa0;E, Leiter &#xa0;LA, Lingvay &#xa0;I, Rosenstock &#xa0;J, Seufert &#xa0;J, Warren &#xa0;ML, Woo &#xa0;V, Hansen &#xa0;O, Holst &#xa0;AG, Pettersson &#xa0;J, Vilsb&#xf8;ll &#xa0;T. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med &#xa0;2016;375:1834&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca &#xa0;MP, Hamburg &#xa0;NM, Creager &#xa0;MA. Stepping into the future of care for patients with PAD. Circulation &#xa0;2024;149:1862&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">38743808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordanstig &#xa0;J, Behrendt &#xa0;C-A, Baumgartner &#xa0;I, Belch &#xa0;J, B&#xe4;ck &#xa0;M, Fitridge &#xa0;R, Hinchliffe &#xa0;R, Lejay &#xa0;A, Mills &#xa0;JL, Rother &#xa0;U, Sigvant &#xa0;B, Spanos &#xa0;K, Szeberin &#xa0;Z, Van De Water &#xa0;W, Antoniou &#xa0;GA, Bj&#xf6;rck &#xa0;M, Gon&#xe7;alves &#xa0;FB, Coscas &#xa0;R, Dias &#xa0;NV, Van Herzeele &#xa0;I, Lepidi &#xa0;S, Mees &#xa0;BME, Resch &#xa0;TA, Ricco &#xa0;J-B, Trimarchi &#xa0;S, Twine &#xa0;CP, Tulamo &#xa0;R, Wanhainen &#xa0;A, Boyle &#xa0;JR, Brodmann &#xa0;M, Dardik &#xa0;A, Dick &#xa0;F, Go&#xeb;ffic &#xa0;Y, Holden &#xa0;A, Kakkos &#xa0;SK, Kolh &#xa0;P, Mcdermott &#xa0;MM. Editor's Choice&#x2014;European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication. Eur J Vasc Endovasc Surg &#xa0;2024;67:9&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">37949800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardman &#xa0;RL, Jazaeri &#xa0;O, Yi &#xa0;J, Smith &#xa0;M, Gupta &#xa0;R. Overview of classification systems in peripheral artery disease. Semin Intervent Radiol &#xa0;2014;31:378&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232437</ArticleId><ArticleId IdType="pubmed">25435665</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuha Ali &#xa0;E, Grazia &#xa0;A, Raveendhara &#xa0;RB, Dennis &#xa0;B, Billy &#xa0;SC, Laya &#xa0;E, Marisa &#xa0;EH, Eric &#xa0;LJ, Kamlesh &#xa0;K, Ildiko &#xa0;L, Glenn &#xa0;M, Rozalina &#xa0;GM, Mary &#xa0;LP, Scott &#xa0;JP, Sarit &#xa0;P, Priya &#xa0;P, Richard &#xa0;EP, Alissa &#xa0;RS, Jane &#xa0;JS, Robert &#xa0;CS, Robert &#xa0;AG. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of Care in Diabetes-2024. Diabetes Care &#xa0;2024;47:S179&#x2013;S218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725811</ArticleId><ArticleId IdType="pubmed">38078592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiatt &#xa0;WR, Hirsch &#xa0;AT, Regensteiner &#xa0;JG, Brass &#xa0;EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vasc Clin Trialists Circ &#xa0;1995;92:614&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">7634476</ArticleId></ArticleIdList></Reference><Reference><Citation>Degischer &#xa0;S, Labs &#xa0;KH, Aschwanden &#xa0;M, Tschoepl &#xa0;M, Jaeger &#xa0;KA. Reproducibility of constant-load treadmill testing with various treadmill protocols and predictability of treadmill test results in patients with intermittent claudication. J Vasc Surg &#xa0;2002;36:83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12096262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordanstig &#xa0;J, Wann-Hansson &#xa0;C, Karlsson &#xa0;J, Lundstr&#xf6;m &#xa0;M, Pettersson &#xa0;M, Morgan &#xa0;MB. Vascular Quality of Life Questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease. J Vasc Surg &#xa0;2014;59:700&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">24342060</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboyans &#xa0;V, Criqui &#xa0;MH, Abraham &#xa0;P, Allison &#xa0;MA, Creager &#xa0;MA, Diehm &#xa0;C, Fowkes &#xa0;FGR, Hiatt &#xa0;WR, J&#xf6;nsson &#xa0;B, Lacroix &#xa0;P, Marin &#xa0;Ben&#xf4;, Mcdermott &#xa0;MM, Norgren &#xa0;L, Pande &#xa0;RL, Preux &#xa0;P-M, Stoffers &#xa0;HE(J), Treat-Jacobson &#xa0;D. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation &#xa0;2012;126:2890&#x2013;2909.</Citation><ArticleIdList><ArticleId IdType="pubmed">23159553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs &#xa0;D, Csiszar &#xa0;B, Biro &#xa0;K, Koltai &#xa0;K, Endrei &#xa0;D, Juricskay &#xa0;I, Sandor &#xa0;B, Praksch &#xa0;D, Toth &#xa0;K, Kesmarky &#xa0;G. Toe-brachial index and exercise test can improve the exploration of peripheral artery disease. Atherosclerosis &#xa0;2018;269:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">29366987</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott &#xa0;MM, Liu &#xa0;K, Guralnik &#xa0;JM, Martin &#xa0;GJ, Criqui &#xa0;MH, Greenland &#xa0;P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg &#xa0;1998;28:1072&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware &#xa0;JE &#xa0;Jr, Sherbourne &#xa0;CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care &#xa0;1992;30:473&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs &#xa0;RM, Szarek &#xa0;M, Brodmann &#xa0;M, Gudz &#xa0;I, Debus &#xa0;ES, Nehler &#xa0;MR, Anand &#xa0;SS, Patel &#xa0;MR, Hess &#xa0;CN, Capell &#xa0;WH, Rogers &#xa0;K, Muehlhofer &#xa0;E, Haskell &#xa0;LP, Berkowitz &#xa0;SD, Hiatt &#xa0;WR, Bonaca &#xa0;MP. Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial. J Am Coll Cardiol &#xa0;2021;78:317&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010631</ArticleId></ArticleIdList></Reference><Reference><Citation>Szarek &#xa0;M, Hess &#xa0;C, Patel &#xa0;MR, Jones &#xa0;WS, Berger &#xa0;JS, Baumgartner &#xa0;I, Katona &#xa0;B, Mahaffey &#xa0;KW, Norgren &#xa0;L, Blomster &#xa0;J, Rockhold &#xa0;FW, Hsia &#xa0;J, Fowkes &#xa0;FGR, Bonaca &#xa0;MP. Total cardiovascular and limb events and the impact of polyvascular disease in chronic symptomatic peripheral artery disease. J Am Heart Assoc &#xa0;2022;11:e025504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9238734</ArticleId><ArticleId IdType="pubmed">35621222</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic &#xa0;V, Tuttle &#xa0;KR, Rossing &#xa0;P, Mahaffey &#xa0;KW, Mann &#xa0;JFE, Bakris &#xa0;G, Baeres &#xa0;FMM, Idorn &#xa0;T, Bosch-Traberg &#xa0;H, Lausvig &#xa0;NL, Pratley &#xa0;R. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med &#xa0;2024;391:109&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">38785209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosiborod &#xa0;MN, Abildstr&#xf8;m &#xa0;SZ, Borlaug &#xa0;BA, Butler &#xa0;J, Rasmussen &#xa0;S, Davies &#xa0;M, Hovingh &#xa0;GK, Kitzman &#xa0;DW, Lindegaard &#xa0;ML, M&#xf8;ller &#xa0;DV, Shah &#xa0;SJ, Treppendahl &#xa0;MB, Verma &#xa0;S, Abhayaratna &#xa0;W, Ahmed &#xa0;FZ, Chopra &#xa0;V, Ezekowitz &#xa0;J, Fu &#xa0;M, Ito &#xa0;H, Lelonek &#xa0;M, Melenovsky &#xa0;V, Merkely &#xa0;B, N&#xfa;&#xf1;ez &#xa0;J, Perna &#xa0;E, Schou &#xa0;M, Senni &#xa0;M, Sharma &#xa0;K, Van Der Meer &#xa0;P, Von Lewinski &#xa0;D, Wolf &#xa0;D, Petrie &#xa0;MC. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med &#xa0;2023;389:1069&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622681</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey &#xa0;AS, Stevens &#xa0;LA, Schmid &#xa0;CH, Zhang &#xa0;Y(L), Castro &#xa0;AF, Feldman &#xa0;HI, Kusek &#xa0;JW, Eggers &#xa0;P, Van Lente &#xa0;F, Greene &#xa0;T, Coresh &#xa0;J. A new equation to estimate glomerular filtration rate. Ann Intern Med &#xa0;2009;150:604&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>